Board Appointments

By

Regulatory News | 24 Feb, 2020

Updated : 07:06

RNS Number : 8226D
Craneware plc
24 February 2020
 

Craneware plc

("Craneware", "the Group" or the "Company")

 

Board Appointments

 

 

24 February 2020 - Craneware (AIM: CRW.L), the market leader in Value Cycle software solutions for the US healthcare market, is pleased to announce the appointments of Alistair Erskine and David Kemp to the Board as Independent Non-Executive Directors.

 

Alistair has held a number of senior positions within the US healthcare sector and will join the Board with immediate effect. He is currently the Chief Digital Health Officer of Partners HealthCare, a US not-for-profit healthcare system which is a leader in the application of clinical information technology to care delivery. He has held academic and governmental roles, including lecturing at Harvard Medical School and a Board Member of the Health Information Technology Standards Committee of the Virginia General Assembly. He holds an MBA from MIT with specialism in Business Analytics and Artificial Intelligence.

 

David, who has extensive UK Public company experience, will join the Board on 1 March 2020. David is currently CFO of the FTSE 250 listed business, John Wood Group PLC, the global projects, operations and consulting business, a position he has held since 2015. He has held a number of CFO and Non-Executive Director positions over the course of his career and is a member of the Institute of Chartered Accountants.

 

Will Whitehorn, Chairman of Craneware plc, commented:

 

"We are delighted to welcome two such experienced individuals to the Board of Craneware as Independent Non-Executive Directors. Alastair's experience both in the clinical and digital operations of US healthcare providers will bring new insights to help guide the evolution of our cloud-based platform, Trisus, while David adds strong UK plc board experience as well as significant merger and acquisition expertise. We look forward to working with them both to fulfil our vision of bringing value to the US healthcare market."

 

 

Director Appointment Information

 

Directorships of David Miller Kemp, aged 49

 

Current directorships

 

UK

John Wood Group PLC

Wood Group Management Services Limited

Wood Group Limited

JWG USA Holdings Limited

Albyn School Limited

 

USA

JWG USA Holdings Inc

Wood Group E&PF Holdings Inc

Wood Group US Holdings Inc

 

Past directorships (in last 5 years)

Wood Group Properties Limited - dissolved on 24 December 2019

John Wood Group US Company - dissolved on 17 December 2019

 



 

Directorships of Alistair Robert Erskine, aged 49

 

USA

 

Current Directorships

Association of Medical Directors of Information Systems (Advisory Board)

Windham Ventures Partners (Advisory Board)

 

Past Directorships (in last 5 years)

Joule Inc - dissolved on 31 December 2019

 

 

 

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

For further information, please contact:

 

 Craneware plc

Peel Hunt        

Investec Bank

Alma


(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR)

+44 (0)131 550 3100

+44 (0)20 7418 8900

+44 (0)20 7597 5970

+44 (0)203 405 0205

Keith Neilson, CEO

Dan Webster

Patrick Robb

Caroline Forde

Craig Preston, CFO

George Sellar

Sebastian Lawrence

Hilary Buchanan


Andrew Clark

Henry Reast

Helena Bogle

 

 

 

About Craneware

 

Craneware (AIM: CRW.L), the leader in automated value cycle solutions, collaborates with U.S. healthcare providers to plan, execute and monitor value-based economic performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 350 staff. Craneware's value cycle management suite includes charge capture, strategic pricing, patient engagement, claims analytics, revenue recovery and retention, and cost and margin intelligence solutions.

 

Learn more at www.craneware.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAKKNBQOBKDFBB

Last news